Jun 22, 2020
twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Sep 20, 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
Aug 22, 2019
Snap Bio's Lead Candidate Overcomes Resistance of Approved Drugs for Liver Cancer
Aug 20, 2019
Q BioMed and Collaborator Chemveda Life Sciences Announce Potential Chemotherapeutic Breakthrough in Liver Cancer
Aug 02, 2019
SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC
Jun 19, 2019
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
May 13, 2019
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
Mar 01, 2019
Many Look Beyond Chemotherapy to Combat the Swelling Incidence of Cancer
Feb 27, 2019
First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma
Feb 25, 2019
Sysmex Inostics' OncoBEAM(TM) Demonstrates Clinical Validity and Superior Performance Versus Pan-cancer NGS for Blood-based Mutation Detection for Hepatocellular Carcinoma
Feb 16, 2019
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Feb 11, 2019
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Feb 05, 2019
Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium
Jan 18, 2019
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
Oct 09, 2018
Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress
Oct 09, 2018
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
Oct 08, 2018
Hepatocellular Carcinoma- Rich Clinical Pipeline can Lead to an Increasing Market Size of USD 3.8 Billion by 2027 for G8 Countries
Sep 11, 2018
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Sep 04, 2018
SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer